Donor-specific antibodies (DSAs) are major mediators of renal allograft injury, and strategies to inhibit DSAs are important in promoting long-term graft survival.
Triptolide exhibits a wide spectrum of antiinflammatory and immunosuppressive activities, and in autoimmune diseases it inhibits autoantibody levels. In this study, we investigated the suppressive role of triptolide in the generation of DSAs in transplant recipients. We found that triptolide treatment of skin allograft recipients in mice significantly suppressed the development of circulating anti-donor-specific IgG and effectively alleviated DSA-mediated renal allograft injury, which led to prolonged 
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alloantibody, animal models, basic (laboratory) research/science, immunosuppression/immune modulation, kidney (allograft) function/dysfunction, kidney transplantation/nephrology, pathology/histopathology, rejection lymphocytes, 19, 20 prevent graft-versus-host disease in mice by suppressing expansion of alloreactive T cells, and prolong renal allograft survival in monkeys when combined with tacrolimus. 21, 22 In addition, triptolide is also a powerful inhibitor of nuclear factor kappa B (NF-κB) and nuclear factor of activated T cells, 18 which is primarily responsible for the therapeutic effects of TWHF in autoimmune diseases. Moreover, triptolide can repress activation of macrophages both in vitro and in vivo, 23, 24 and the expression of complement C3 in proximal tubular epithelial cells. 25 To date, limited studies have explored the effects of triptolide on antibodies.
Three research groups showed that triptolide and its derivative effectively reduced deposits of antibodies in kidneys of animals with IgA nephropathy and systemic lupus erythematosus, and decreased circulating levels of anti-double-stranded DNA IgG antibodies in lupus nephritis, [26] [27] [28] 
| MATERIALS AND METHODS

| Reagents
Triptolide (C20H24O6, purity: 99.9%) was obtained from the
Chinese National Institute for Control of Pharmaceutical and
Biological Products (Beijing, China). The triptolide prodrug MC002
(citric acid dimethylamine acetyl triptolide ester, C30H39NO14) was purchased from Medicass Biotechnology Co., Ltd (Beijing, China). Triptolide was dissolved in dimethylsulfoxide (DMSO), whereas MC002 was dissolved in normal saline. Antibodies used for immunofluorescent staining were purchased from R&D Systems anti-IgM. 
| Mice
| Transplant surgery
Full-thickness skin grafts (0.8~1.0 × 1 cm 2 ) from tails of C3H donor mice were transplanted onto the backs of BALB/C recipient mice. Murine kidney transplantation models were established using techniques similar to those described previously. 29 Renal grafts were positioned on the right side with bilateral native kidneys removed. Graft rejection leading to death was used as the study endpoint, whereas mice with long-term surviving grafts were euthanized at postoperative day 100.
| Experimental groups
The kidney allograft acute AMR (or antibody-mediated rejection) disease model was established by transplanting C3H donor kidneys to BALB/C recipient mice on day 4 after receiving skin grafts from C3H donor mice. AMR recipients were assigned randomly to 2 groups: (1) the AMR-TPL group, triptolide (TPL) prodrug MC002
was administrated subcutaneously at dose of 1 mg/kg/per day, from day 0 to day 4 after skin transplantation, and another 2 times of 0.5 mg/kg on day 1 and day 3 after kidney transplantation; and (2) the presensitized (AMR) group, 0.3 mL/per mice normal saline was applied to vehicle-treated control mice. Kidney transplantations from C3H to BALB/C mice without presensitization performed as the nonpresensitized control group, whereas kidney transplantations from BALB/C to BALB/C mice acted as the isograft control. For mice that underwent skin transplantations without receiving subsequent kidney transplantations, the recipients were assigned to 2 groups: (1) the TPL group, MC002 was administrated subcutaneously at a dose of 1 mg/kg, every other day, from day 0 to day 28 after skin transplantation; and (2) the non-TPL group, normal saline 0.3 mL/per mice was applied every other day to the vehicle-treated control group.
| Circulating donor-specific antibodies assay
The levels of circulating antidonor DSAs of IgG and IgM in recipient sera at indicated time points were assessed by flow cytometry as described previously. 30 Briefly, recipient sera were incubated with C3H donor splenocytes at 37°C for 30 minutes, and washed cells were then incubated with FITC-labeled anti-mouse IgG and rhodamine red-conjugated anti-mouse IgM at 4°C for 1 hour. Cells were analyzed by flow cytometry with results expressed as mean fluorescence intensity to reflect individual serum DSA levels.
| Histology
At the time of rejection or on day 5 after kidney transplantation, the kidney grafts were harvested, formalin fixed, and paraffin embedded.
Tissue samples were sectioned at 4 μm, deparaffinized, and rehy- 
| Flow cytometry
The fresh kidney grafts were milled gently in phosphate-buffered sa- 
| Isolation and in vitro culture system for B cells
Human peripheral mononuclear leukocytes were isolated by Ficoll density gradient centrifugation. Purification of B cells was achieved with a MACS column purification system (MiltenyiBiotec). B cells were incubated in RPMI-1640 supplemented with 10% FBS and 5 μg/ml CpG plus 5 μg/ml anti-IgM as described previously. Immunocytometry Systems, San Diego, CA) using Cell Quest software.
| Enzyme-linked immunosorbent assay (ELISA)
Concentrations of human immunoglobulins in the supernatants from in vitro culture systems were detected using ELISA kits according to the manufacturers' instructions (Bethyl Laboratories, Inc., for IgM, IgA, and IgG).
| Ig diversity assay
The IgVH3 diversity assay used was based on a modification of a previously described procedure. 33 Total RNA was isolated using the RNeasy procedure (Qiagen, Valencia, CA) and reverse-transcribed with a JH consensus reverse primer, 5′ -TGAGGATCCGGTGAC CAG GGTGCCTTGGCCCCA G. The complementary DNA was amplified with a VH3 consensus forward primer, 5′ -GTCCCT GAG ACT CTC CTGTG, and the JH consensus reverse primer using the following conditions: 1 cycle of 2 minutes at 94°C followed by 35 cycles of 30 seconds at 94°C, 45 seconds at 58°C, and 30 seconds at 72°C.
The quantitative real-time polymerase chain reaction (qPCR) products were untreated or digested with AluI, and were subsequently separated on a 10% polyacrylamide nondenaturing gel. The band intensities of the untreated and digested PCR products were measured using Adobe Photoshop CS4. The ratios of digested PCR products to the untreated counterparts were calculated as the VH3 diversity index.
| qPCR
Trizol reagent (Invitrogen) was used to isolate total RNA of B cells from in vitro culture systems and of allografts from different groups.
Aliquots (2 μg) of the RNA were reverse-transcribed using MMLV reverse transcriptase (Promega). The primers used are listed in Table   S1 . The PCR was performed in triplicate using SYBR Green Real-Time PCRMasterMix (TOYOBO) in a Roche LightCycler480 System. All results are presented in arbitrary units relative to β-actin expression.
| Statistical analysis
The Student's t-test was utilized to compare the differences between the 2 groups. Graft survival among groups was compared using the log-rank test. Data were shown as means ± standard deviation (SD).
Differences with P < .05 were considered statistically significant.
| RESULTS
| Triptolide inhibits the generation of DSAs in vivo
In this study, we used a mouse skin transplant model to investigate the effect of triptolide on DSA production. Specifically, we transplanted C3H skin into BALB/C recipients, and groups of recipient mice were treated with or without triptolide prodrug MC002. As shown in Figure 1A , IgG levels gradually increased at day 6 after skin transplant; before this time point, IgG levels were low and almost constant, whereas from day 6 onward, the IgG levels continued to increase as time progressed. However, MC002 treatment significantly reduced this upward trend, with a 54.2%, 63.5%, 41.1%, 41.2%, and 51.0% reduction at days 8, 12, 16, 24, and 28 after transplantation, respectively, compared to vehicle treatment. In contrast, IgM levels were extremely low relative to IgG levels, and showed little response to skin allograft transplant; thus the difference of IgM levels between the MC002-treated group and nontreated group was not statistically significant, although MC002 displayed an inhibitory trend in IgM levels ( Figure 1B ).
| Triptolide inhibits B cell differentiation and antibody secretion in vitro
To better understand the mechanisms of triptolide in suppressing antibody production, we further performed a series of in vitro assays using human B cells. Because triptolide can induce cell apoptosis, 17 to exclude the potential confounding effect that decreased antibody levels in the triptolide-treated group might result from B cells apoptosis, an independent experiment was carried out to assess the proapoptotic function of triptolide on B cells. To be specific, B cells were cultured in the presence of triptolide at different concentrations ranging from 0.04 ng/mL to 4 μg/mL for 8 days, and PI staining was subsequently constructed to evaluate cell survival.
Our data showed that treatment with triptolide resulted in increased cell death in a dose-dependent manner ( Figure 2A) . Moreover, Figure 2F ).
| Triptolide attenuates DSA-mediated renal allograft injury and prolongs graft survival
Because triptolide is shown to inhibit the generation of DSAs, we set up an in vivo mouse kidney model to assess whether triptolide might alleviate DSA-mediated allograft injury and rejection. We adopted a previously published protocol to induce AMR in the mouse with some modification. 30, 34 Briefly, BALB/C recipients were presensitized with C3H donor skin grafts 4 days before receiving C3H kidney transplants.
Our data revealed that recipients injected with MC002 had a prolonged graft survival time compared with vehicle-treated group, with a mean survival time of 27.56 ± 12 vs 6.43 ± 0.87 days; about 50% of the grafts from the triptolide-treated mice survived beyond 14 days, whereas all grafts were rejected before day 9 in the untreated group ( Figure 3A) . Flow cytometry results showed that serum levels of IgG F I G U R E 1 Triptolide inhibits anti-donor-specific IgG development in vivo. BALB/C mice that received skin allografts from C3H donors were treated with (TPL group) or without MC002 (non-TPL group) for 28 days. Recipient sera collected at the indicated time points were reacted with donor spleen cells and evaluated for cell staining by flow cytometry. Circulating levels of detected donor specific antibodies (DSAs) are expressed as mean fluorescence intensity (MFI) ± SD (n = 6). (A) Triptolide significantly inhibited generation of DSA-IgG. (B) Triptolide had little effect on DSA-IgM production. *P < .05; **P < .01; ***P < .001
and IgM from untreated recipients were elevated on day 5 after kidney transplantation compared to those on the day of skin transplantation, whereas MC002 treatment not only conspicuously inhibited this upward trend, but also decreased IgG levels on day 5 after transplantation. The difference in IgM levels between the MC002-treated group and the untreated group was not statistically significant ( Figure 3B ). ELISA. Somatic hypermutation of B cells (E) and isotypes of Ig (F) were examined by IgVH3 diversity assay and real-time PCR, respectively. Fold changes were relative to Fresh control. Data shown in B-E represent means ± SD of at least 3 independent experiments. *P < .05; **P < .01; ***P < .001 compared with the DMSO-treated group Moreover, histological analysis revealed that untreated mice exhibited focal interstitial inflammatory cells infiltrates, peritubular capillary (PTC) dilation and capillaritis, and intense and diffuse C3d and IgG deposition in PTC, which were consistent with the features of acute AMR, whereas MC002 treatment significantly attenuated all of these phenomena ( Figure 3C-D) .
| Triptolide reduces the numbers of B cells, plasma cells, and memory B cells in the host spleens and renal allografts
As shown in Figure 4 , 
| Triptolide reduces infiltration of inflammatory cells in renal allografts
Besides B cells, other graft-infiltrating inflammatory cells were characterized by immunofluorescence confocal staining or flow cytometry assay on day 5 after kidney transplantation. As showed in Figure 5A ,B, macrophages were abundant in grafts, with the predominant phenotype of classically activated M1 rather than alternately activated M2, whereas triptolide treatment significantly 
| DISCUSSION
In this study, we provided strong evidence that triptolide inhibits DSA production primarily through suppression of B cell differentiation, and in a mouse kidney transplant model, it attenuates antibody-mediated organ injury and prolongs renal allograft survival. Consequently, triptolide treatment resulted in a significant reduction in the numbers and frequencies of multiple cell types that infiltrate the allografts during
AMR.
Although other studies have demonstrated that triptolide reduced the development of antibodies in IgA nephropathy and systemic lupus erythematosus, 26, 27 it is still unknown whether triptolide can suppress DSAs, which significantly contribute to allograft injury and rejection.
Here we proved for the first time that triptolide dramatically reduced the circulating levels of DSA-IgG in a mouse skin transplant model.
Current treatment strategies for controlling DSAs are focused on removing preexisting antibodies or eliminating B cells, [8] [9] [10] [11] [12] but these interventions seem to be not as effective as expectation, although a combination of several strategies has been employed to pursue a synergistic effect. [13] [14] [15] [16] Due to its prominent suppressive function in DSAs and its properties of abundance, triptolide may be considered as an effective and economical treatment for desensitization and AMR in the clinical setting. IgG by plasma cells. Second, our data showed that triptolide restrained antibody production by inhibiting somatic hypermutation and class switch recombination of B cells. B lymphocytes achieve repertoire F I G U R E 3 Triptolide attenuates DSA-mediated renal allograft injury and prolongs allograft survival. The kidney allograft acute AMR disease model was established by transplanting C3H donor kidneys to BALB/C recipients on day 4 after receiving C3H skin grafts. Recipients were treated with (AMR-TPL) or without MC002 (AMR). BALB/C mice receiving C3H kidney without priming to skin graft (nonpresensitized) and isogenic kidney transplantation in BALB/C mice (isograft) acted as controls. NS, not significant. *P < .05; **P < .01. In summary, we demonstrate that triptolide was capable of suppressing DSA development in vivo and B cell differentiation and antibody production in vitro. Subsequently, we provide evidence that triptolide attenuated antibody-mediated renal allograft injury and rejection. These findings highlight the importance of triptolide in suppression of DSAs and suggest new therapeutic opportunities for triptolide in the prevention of antibody-mediated injury and rejection in sensitized patients with kidney transplants with a high probability of AMR.
